<DOC>
	<DOCNO>NCT02645253</DOCNO>
	<brief_summary>This randomize , single-blind , placebo-controlled , sequential-group study ass safety tolerability well drug ( AZD7594 ) affect body ( pharmacodynamics [ PD ] ) body affect drug ( pharmacokinetics [ PK ] ) AZD7594 give single multiple ascend dos daily inhalation healthy male Japanese subject , compare placebo ( non-active drug )</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Pharmacokinetics AZD7594 Inhaled Formulation Healthy Japanese Men</brief_title>
	<detailed_description>This phase I , randomize , single-blind , placebo control , sequential-group design study ass safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) AZD7594 single multiple ascend dos give daily inhalation healthy male Japanese subject , compare placebo</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . Provision sign date , write informed consent prior study specific procedure . 2 . Healthy male Japanese subject age 20 45 year suitable vein cannulation repeat venipuncture . A Japanese male subject define born Japan , parent four grandparent Japanese . The subject must live outside Japan 5 year . 3 . Have body mass index ( BMI ) 18 30 kg/m2 inclusive weigh least 45 kg 100 kg inclusive . 4 . Provision sign , write date informed consent optional genetic research Note : If subject decline participate genetic component study , penalty loss benefit subject . The subject exclude aspect study describe protocol . 1 . History clinically significant disease disorder , opinion investigator , may either put subject risk participation study , influence result subject 's ability participate study . 2 . History presence gastrointestinal ( GI ) , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug . 3 . Any clinically significant illness , medical/surgical procedure , trauma within 4 week first administration investigational drug administration . 4 . Any contraindication use vagolytic sympaticomimetic drug , judge investigator . 5 . Any clinically significant abnormality clinical chemistry , hematology , urinalysis , physical examination , vital sign , electrocardiogram ( ECG ) lung function result baseline , judge investigator . 6 . Known Gilbert 's syndrome , family history Gilbert 's syndrome suspicion Gilbert 's syndrome base liver function test . 7 . Use systemic glucocorticosteroids within 6 week enrollment . 8 . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) . 9 . Known suspected hypersensitivity investigational product excipients . 10 . Plasma donation within one month screen blood donation/blood loss &gt; 500 mL 3 month prior screen . 11 . Abnormal vital sign , 10 minute supine rest , define follow : Systolic blood pressure ( BP ) &lt; 90mmHg &gt; 140 mmHg Diastolic BP &lt; 60mmHg &gt; 90 mmHg Pulse rate &lt; 40 &gt; 85 beat per minute ( bpm ) 12 . Any clinically significant abnormality rhythm , conduction morphology rest ECG clinically significant abnormality 12lead ECG , consider investigator may interfere interpretation QTc interval change , include abnormal STTwave morphology , particularly protocol define primary lead leave ventricular hypertrophy . 13 . Prolonged QT interval correct heart rate ( HR ) use Fridericia 's formula ( QTcF ) &gt; 450 m family history long QT syndrome . 14 . PR ( PQ ) interval shorten &lt; 120 m ( PR &gt; 110 m &lt; 120 m acceptable evidence ventricular preexcitation ) . 15 . PR ( PQ ) interval prolongation ( &gt; 240 m ) intermittent second ( Wenckebach block asleep exclusive ) third degree AV block , AV dissociation . 16 . Persistent intermittent complete bundle branch block ( BBB ) , incomplete bundle branch block ( IBBB ) , intraventricular conduction delay ( IVCD ) QRS &gt; 110 m . Subjects QRS &gt; 110 m &lt; 115 m acceptable evidence , example , ventricular hypertrophy preexcitation . 17 . Known suspected history drug abuse , judge investigator . 18 . Current smoker smoke used nicotine product within previous 3 month . 19 . History alcohol abuse excessive intake alcohol , judge investigator . 20 . Positive screen drug abuse cotinine ( nicotine ) screen admission unit . 21 . History severe allergy/hypersensitivity ongoing clinically significant allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class ADZ7594 . 22 . Excessive intake caffeine contain drink food ( e.g. , coffee , tea , chocolate ) , judge investigator . 23 . Use drug enzyme induce property St John 's Wort within 3 week prior first administration investigational drug . 24 . Use prescribed nonprescribed medication include antacid , analgesic ( paracetamol/acetaminophen ) , herbal remedy , megadose vitamin ( intake 20 600 time recommended daily dose ) mineral 2 week prior first administration investigational drug long medication long halflife . 25 . Has receive another new chemical entity ( define compound approve market US ) within 30 day least 5 halflives ( whichever longer ) first administration investigational drug study . The period exclusion begin 3 month final dose 1 month last visit whichever long . Note : Subjects consent screen , randomize study previous phase I study , exclude . 26 . Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order . 27 . Subjects previously receive AZD7594 . 28 . Involvement Astra Zeneca study site employee close relative . 29 . Judgment investigator subject participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction requirement . 30 . Subjects vegans medical dietary restriction . 31 . Subjects communicate reliably investigator . It acceptable make use interpreter . The informed consent document ( ICD ) must available Japanese language . In addition , follow regarded criterion exclusion genetic research : 32 . Previous bone marrow transplant . 33 . Nonleukocyte deplete whole blood transfusion within 120 day date genetic sample collection</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Glucocorticoid receptor modulator</keyword>
	<keyword>Healthy male subject</keyword>
</DOC>